Angela Bellini

Paris, 75005, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Tumor-on-chip as a personalized platform for rapid drug testing in breast cancer.

Tumor-on-chip as a personalized platform for rapid drug testing in breast cancer.

Journal: Cell reports. Medicine

Published: November 24, 2025

Differential chromatin accessibility response to retinoic acid in neuroblastoma with ATRX in-frame-deletions versus ATRX loss-of-function.

Differential chromatin accessibility response to retinoic acid in neuroblastoma with ATRX in-frame-deletions versus ATRX loss-of-function.

Journal: Neoplasia (New York, N.Y.)

Published: August 06, 2025

Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology.

Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology.

Journal: NPJ precision oncology

Published: July 23, 2025

Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology.

Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology.

Journal: NPJ precision oncology

Published: July 23, 2025

Harmonization of Reporting of ALK Genetic Alterations in Neuroblastoma: A SIOPEN Biology Study.

Harmonization of Reporting of ALK Genetic Alterations in Neuroblastoma: A SIOPEN Biology Study.

Journal: The Journal of molecular diagnostics : JMD

Published: April 08, 2025

ATRX mutations mediate an immunogenic phenotype and macrophage infiltration in neuroblastoma.

ATRX mutations mediate an immunogenic phenotype and macrophage infiltration in neuroblastoma.

Journal: Cancer letters

Published: November 07, 2024

Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy.

Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 06, 2024

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 29, 2022

Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma.

Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma.

Journal: Journal for immunotherapy of cancer

Published: June 21, 2022

Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).

Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 11, 2021

Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma.

Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma.

Journal: Nature communications

Published: January 04, 2021

ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations.

ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations.

Journal: Oncotarget

Published: March 26, 2019

Showing 1-12 of 22

Last Updated: 09/26/2026